Hoth Therapeutics Releases Preclinical Safety Data For Cancer Fighting HT-KIT Including 100% Clean Safety Profile And No Adverse Effects On Kidney, Spleen, Or Thymus

Author: Benzinga Newsdesk | June 18, 2025 07:24am

HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck

HOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing.

Study Results:

• Liver weight increased from 1.11g → 1.32g across 0 → 3.0 mg/kg
• No adverse effects on kidney, spleen, or thymus
• 100% clean safety profile — no visible lesions or gross pathology
• Validates safety of HT-KIT in vivo

Robb Knie, CEO: "These results strengthen our confidence in HT-KIT as we advance toward clinical trials. A strong safety signal with dose responsiveness and no toxicity gives us a clear path forward."

Posted In: HOTH